Apex Physics Partners, the largest outsourced medical physics services company in North America, announced Wednesday a new partnership with INphysics, Indiana’s market leader for therapy medical physics and dosimetry services. INphysics will complement Apex’s existing diagnostic medical physics footprint, having partnered with Advanced Medical Physics and its leader Will Breeden earlier this year. Based in Indianapolis, INphysics is a multidisciplinary consulting firm offering radiation therapy medical physics and dosimetry services to leading hospital systems and cancer centers throughout Indiana and the United States.
Labcorp (NYSE: LH), a leading global life sciences company, announced Monday that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay.
Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “us”, “our”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced today that it has entered into a definitive agreement to acquire Agena Bioscience, Inc. (“Agena”) for a cash purchase price of $300 million, subject to customary purchase price adjustments. Agena is headquartered in San Diego, California and is a leading molecular diagnostics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally.
BelHealth Investment Partners, LLC (“BelHealth”) is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company (“GTG”). The transaction was structured in a combination of cash and stock of GTG. Founded in 2013, GGC, managed its non-US based direct-to-consumer (DTC) genetic testing business consisting of trademarks, websites, and a strong network of brand agents via two offices based in Malta and Australia.
Heska Corporation (NASDAQ: HSKA – News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced today that the Company has acquired majority ownership of Biotech Laboratories U.S.A. LLC (“Biotech”), an leading developer of rapid assay diagnostics testing, from Biotech Holdings U.S.A. LLC (“Acquisition”). Founded in 2016 and headquartered in Rockville, Maryland, Biotech develops a full line of rapid point-of-care tests to detect antigens and antibodies associated with infectious and parasitic diseases of animals.
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has completed the sale of specialty diagnostics company Orgentec Diagnostika to Sebia. Headquartered in Lisses, France, Sebia is a world-leading provider of technology used for in-vitro diagnostic testing. Water Street invested in Orgentec in 2014. Over the next seven years, the health care firm leveraged its expertise and network of resources in the diagnostics sector to transform Orgentec into one of the world’s leading providers of specialty diagnostic solutions for autoimmune and infectious diseases.
Biomeme, the leading provider of portable PCR testing solutions, has signed a definitive agreement to acquire Predigen, a privately held diagnostic company and emerging leader in precision medicine focused on host response diagnostics. Predigen’s acquisition will expand Biomeme’s capabilities across infectious disease and clinical microbiology, business management, and commercialization.
Quest Diagnostics, the nation’s leading provider of diagnostic information services, announced it has acquired select assets of Nationwide Laboratory Services (NLS), an independent clinical diagnostics laboratory headquartered in Boca Raton, FL with over 25 years of patient centric service throughout the country. With the acquisition, Quest will broaden access to diagnostic innovation and insights empowering better health for more communities in South Florida. Testing services provided by NLS will transition to Quest’s full-service laboratory in Miramar, FL. Quest will also acquire select patient service sites in South Florida.
LumiraDx, a next-generation point of care diagnostics testing company, and CA Healthcare Acquisition Corp (Nasdaq: CAHC), a special purpose acquisition company focused on investing in a growth-oriented healthcare company, announced they have revised the valuation of their previously announced transaction based on various considerations. The new transaction terms adjust the pro forma enterprise value of LumiraDx (including CAHC) from $5 billion to $3 billion excluding any cash held in trust by CAHC.
The European Union’s executive arm said it was opening a probe into Illumina Inc.’s decision to complete its $7.1 billion purchase of Grail Inc. despite a continuing antitrust investigation. The European Commission said Friday that the probe would assess whether Illumina’s move breached the bloc’s rules calling for companies to put on hold mergers while the EU is investigating competition concerns.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.